The majority of ACT studies focus on evoking CD8+ cytotoxic T lymphocytes (CTL) -mediated anti-tumor responses, due to the ability of CD8+ CTL to kill tumor cells directly in a major histocompatibilty complex I (MHC-I) -restricted manner. Here, CD8A is linked to neoplasm.